Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Asthma drug enerzair under Real-World watch

NCT ID NCT05274425

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study tracks 600 adults with asthma who are already prescribed Enerzair inhaler. Over 24 weeks, researchers will monitor side effects and how well the drug controls asthma in everyday life. No new treatment is given; it simply observes routine care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Enerzair (indacaterol/glycopyrronium/mometasone) inhaler
What this could lead to
If successful, this study could confirm that Enerzair works well and is safe for everyday asthma control in a broad range of patients.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only follows patients for 24 weeks, so long-term effects are not assessed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

683 people

The number who actually took part.

Started

May 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects who received at least one dose of Enerzair inhalation capsule via Breezhaler and that have provided consent for their data collection.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult patients (≥18 years of age) with a physician's diagnosis of asthma, who are prescribed Enerzair inhalation capsule (indacaterol acetate/ glycopyrronium bromide/mometasone furoate; 150/50/80, 150/50/160 μg) via Breezhaler, as per the approved label information 2. Patients who participate in the study after signing the consent form for data collection and use (Data Privacy ICF) after receiving a clear explanation of the objectives and nature of the study from the investigator Exclusion Criteria: 1. Patients who are contraindicated for this medicinal product as described in the Precautions for Use in the label information (package insert) A. Patients with hypersensitivity reaction to this medicinal product or any of its constituents B. Because this medicinal product contains lactose, patients with hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption, etc. 2. Patients with acute asthma symptoms, including acute episodes of bronchospasm, for which a short-acting bronchodilator is required 3. Patients participating in other interventional clinical trials

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma

Contacts and locations

Locations

  • Novartis Investigative Site

    Daegu, Dalseo gu, 42602, South Korea

  • Novartis Investigative Site

    Wŏnju, Gangwon-do, 26426, South Korea

  • Novartis Investigative Site

    Bucheon-si, Gyeonggi-do, 14584, South Korea

  • Novartis Investigative Site

    Bundang Gu, Gyeonggi-do, 13620, South Korea

  • Novartis Investigative Site

    Goyang-si, Gyeonggi-do, 10475, South Korea

  • Novartis Investigative Site

    Yangsan, Gyeongsangnam-do, 50612, South Korea

  • Novartis Investigative Site

    Jeonju, Jeollabuk-do, 54907, South Korea

  • Novartis Investigative Site

    Suncheon, Jeollanam-do, 540-719, South Korea

  • Novartis Investigative Site

    Cheongju-si, North Chungcheong, 28644, South Korea

  • Novartis Investigative Site

    Seoul, Seoul, 06351, South Korea

  • Novartis Investigative Site

    Busan, 49201, South Korea

  • Novartis Investigative Site

    Daegu, 705703, South Korea

  • Novartis Investigative Site

    Gwangju, 501171, South Korea

  • Novartis Investigative Site

    Gyeonggi-do, 14353, South Korea

  • Novartis Investigative Site

    Gyeongsangnam Do, 630-522, South Korea

  • Novartis Investigative Site

    Seoul, 03722, South Korea

  • Novartis Investigative Site

    Seoul, 04763, South Korea

  • Novartis Investigative Site

    Seoul, 05505, South Korea

  • Novartis Investigative Site

    Seoul, 06273, South Korea

  • Novartis Investigative Site

    Seoul, 134 727, South Korea

  • Novartis Investigative Site

    Seoul, 2447, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.